Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-09-26 00:00:00 ET · period of report 2023-09-22 · accession 0000886163-23-000069 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-26 | 2023-09-22 | LGND | Zimmermann Martine | Dir | A - Grant | $0.00 | +2,285 | 2,285 | New | $0 |
| D | 2023-09-26 | 2023-09-22 | LGND | Zimmermann Martine | Dir | A - Grant | $0.00 | +11.3K | 11.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-22 | A | A | 2,285 | $0.00 | 2,285 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on September 22, 2024; September 22, 2025; and September 22, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-09-22 | A | A | 11,345 | $0.00 | 11,345 | D | $59.08 · — to 2033-09-22 | 11,345 Common Stock | (F2) Grant of Stock Options that will vest and become exercisable in three substantially equal annual installments on September 22, 2024; September 22, 2025; and September 22, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |